These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
270 related items for PubMed ID: 25423630
1. Frequency of vitreomacular interface disease in patients presenting to a tertiary care institution. Xu LT, Punjabi OS, Shao J, Ehlers JP, Srivastava SK, Singh RP, Kaiser PK. Ophthalmic Surg Lasers Imaging Retina; 2014; 45(6):517-20. PubMed ID: 25423630 [Abstract] [Full Text] [Related]
2. Real-life experience after intravitreal ocriplasmin for vitreomacular traction and macular hole: a spectral-domain optical coherence tomography prospective study. Chatziralli I, Theodossiadis G, Parikakis E, Datseris I, Theodossiadis P. Graefes Arch Clin Exp Ophthalmol; 2016 Feb; 254(2):223-33. PubMed ID: 25940555 [Abstract] [Full Text] [Related]
12. Baseline Predictors of Vitreomacular Adhesion/Traction Resolution Following an Intravitreal Injection of Ocriplasmin. Jackson TL, Regillo CD, Girach A, Dugel PU, MIVI-TRUST Study Group. Ophthalmic Surg Lasers Imaging Retina; 2016 Aug 01; 47(8):716-23. PubMed ID: 27548448 [Abstract] [Full Text] [Related]
13. Surgical Outcomes for Persistent Macular Hole After Ocriplasmin. Lee GD, Taney LS, Rogers AH, Shah CP, Duker JS, Baumal CR. Ophthalmic Surg Lasers Imaging Retina; 2015 Aug 01; 46(7):732-6. PubMed ID: 26247454 [Abstract] [Full Text] [Related]
14. Delayed full-thickness macular hole closure without vitreomacular traction release following ocriplasmin injection. Abou Ltaif S, Herbert L. BMJ Case Rep; 2015 Sep 10; 2015():. PubMed ID: 26359463 [Abstract] [Full Text] [Related]
15. Ocriplasmin treatment for vitreomacular traction in real life: can the indication spectrum be expanded? Manousaridis K, Peter-Reichart S, Mennel S. Graefes Arch Clin Exp Ophthalmol; 2017 Oct 10; 255(10):1907-1916. PubMed ID: 28681138 [Abstract] [Full Text] [Related]
17. [Pharmaological vitreolysis with ocriplasmin as a treatment option for symptomatic focal vitreomacular traction with or without macular holes (≤400 μm) compared to tranconjunctival vitrectomy]. Maier M, Abraham S, Frank C, Lohmann CP, Feucht N. Ophthalmologe; 2017 Feb 10; 114(2):148-154. PubMed ID: 27444007 [Abstract] [Full Text] [Related]
18. The Efficacy and Safety Profile of Ocriplasmin in Vitreomacular Interface Disorders. Shaikh M, Miller JB, Papakostas TD, Husain D. Semin Ophthalmol; 2017 Feb 10; 32(1):52-55. PubMed ID: 27786583 [Abstract] [Full Text] [Related]
19. Outer retina reflectivity changes on sd-oct after intravitreal ocriplasmin for vitreomacular traction and macular hole. Quezada-Ruiz C, Pieramici DJ, Nasir M, Rabena M, Steinle N, Castellarin AA, Dhoot D, Couvillion S, See RF, Avery RL. Retina; 2015 Jun 10; 35(6):1144-50. PubMed ID: 25961122 [Abstract] [Full Text] [Related]
20. INTRAVITREAL OCRIPLASMIN IN CLINICAL PRACTICE: Predictors of Success, Visual Outcomes, and Complications. Feng HL, Roth DB, Hasan A, Fine HF, Wheatley HM, Prenner JL, Shah SP, Modi KK, Feuer WJ. Retina; 2018 Jan 10; 38(1):128-136. PubMed ID: 28106706 [Abstract] [Full Text] [Related] Page: [Next] [New Search]